RT @paddster: Thanks #DIAEurope2020 for the smooth running of a very interesting session. For more on the topics I covered in my talk, you…
Thanks #DIAEurope2020 for the smooth running of a very interesting session. For more on the topics I covered in my talk, you can see this open access article, written with Priya Bahri https://t.co/oeXFFnBK6k #patientengagement #patientsafety #medicines
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to engage, and how do we measure our success? Read more in EJCP: https://t.co/xLpQRG89Fi @UvA_Amsterdam @EMA_News https://t.co/VHwxDbBALw
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagement, and how do we measure it? This review in the European Journal of Clinical Pharmacology offers some answers: https://t.co/xLpQRG89Fi
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
RT @UMCGlobalSafety: Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to enga…
Good #pharmacovigilance builds on patients' and doctors' engagement in #MedicineSafety. But how do we get them to engage, and how do we measure our success? Read more here: https://t.co/xLpQRG89Fi
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
RT @UMCGlobalSafety: We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagemen…
We often argue that better #pharmacovigilance requires more engaged patients. But what exactly do we mean by engagement, and how do we measure it? This review in the European Journal of Clinical Pharmacology offers some answers: https://t.co/xLpQRG89Fi @U
RT @paddster: How can regulatory bodies such as the European Medicines Agency better understand 'engagement' and better evaluate their enga…
RT @paddster: How can regulatory bodies such as the European Medicines Agency better understand 'engagement' and better evaluate their enga…
RT @paddster: How can regulatory bodies such as the European Medicines Agency better understand 'engagement' and better evaluate their enga…
How can regulatory bodies such as the European Medicines Agency better understand 'engagement' and better evaluate their engagement activities? Our new article provides a conceptual and methodological framework for doing so #risk #regulation #medicines ht